MINNEAPOLIS, Oct. 16 /PRNewswire/ -- Urologix, Inc. (Nasdaq: ULGX)
announced today that it has filed a registration statement with the Securities
and Exchange Commission covering a proposed public offering of 1,500,000
shares of its common stock.  All of the shares are being offered by the
company.  The company has granted the underwriters an option to purchase an
additional 225,000 shares to cover over-allotments, if any.
    BT Alex. Brown Incorporated will lead manage the offering.  Dain Bosworth
Incorporated and PaineWebber Incorporated will co-manage the offering.
    The company intends to use the net proceeds of the offering to fund sales
and marketing expenditures, to expand manufacturing capacity, and for working
capital and other general corporate purposes.
    Urologix, Inc., based in Minneapolis, develops, manufactures and markets
minimally invasive medical devices for the treatment of urological diseases.
The company has developed the Targis System, a non-surgical, anesthesia-free,
catheter-based therapy that uses a proprietary microwave technology for the
treatment of benign prostatic hyperplasia (BPH), a disease that affects over
23 million men worldwide.  The Targis System has been approved for marketing
in the United States, the European Union, Japan and Canada.
    A registration statement relating to these securities has been filed with
the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to
the time the registration statement becomes effective.  This press release
shall not constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of these securities in any State in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such State.

Link to this page: